BidaskClub Downgrades Audentes Therapeutics (BOLD) to Buy
Audentes Therapeutics (NASDAQ:BOLD) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Wednesday.
A number of other research firms also recently weighed in on BOLD. ValuEngine downgraded shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Raymond James Financial began coverage on shares of Audentes Therapeutics in a research note on Thursday, October 12th. They set a “market perform” rating on the stock. BMO Capital Markets began coverage on shares of Audentes Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $35.00 price target on the stock. Zacks Investment Research downgraded shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 17th. Finally, Bank of America reaffirmed a “buy” rating and set a $33.00 price target (up previously from $23.00) on shares of Audentes Therapeutics in a research note on Friday, September 22nd. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $28.29.
Audentes Therapeutics (NASDAQ:BOLD) traded up $1.46 during trading hours on Wednesday, reaching $28.89. 169,100 shares of the company’s stock were exchanged, compared to its average volume of 148,119. Audentes Therapeutics has a 12 month low of $13.90 and a 12 month high of $33.43.
In other news, major shareholder Orbimed Advisors Llc sold 672,000 shares of the stock in a transaction on Friday, September 29th. The shares were sold at an average price of $28.25, for a total value of $18,984,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP David Nagler sold 3,750 shares of the stock in a transaction on Friday, September 15th. The stock was sold at an average price of $25.00, for a total transaction of $93,750.00. Following the completion of the sale, the senior vice president now directly owns 3,750 shares of the company’s stock, valued at approximately $93,750. The disclosure for this sale can be found here. Insiders sold 761,500 shares of company stock valued at $21,457,100 in the last three months. Company insiders own 47.30% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in BOLD. SG Americas Securities LLC acquired a new stake in Audentes Therapeutics during the 3rd quarter valued at $143,000. Nationwide Fund Advisors grew its holdings in Audentes Therapeutics by 288.9% during the 2nd quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 6,384 shares in the last quarter. State of Wisconsin Investment Board acquired a new stake in Audentes Therapeutics during the 2nd quarter valued at $210,000. Rhumbline Advisers acquired a new stake in Audentes Therapeutics during the 2nd quarter valued at $252,000. Finally, Virtu KCG Holdings LLC acquired a new stake in Audentes Therapeutics during the 2nd quarter valued at $257,000. 78.99% of the stock is owned by institutional investors and hedge funds.
WARNING: “BidaskClub Downgrades Audentes Therapeutics (BOLD) to Buy” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/08/bidaskclub-downgrades-audentes-therapeutics-bold-to-buy.html.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Stock Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related stocks with our FREE daily email newsletter.